risperidone has been researched along with Anankastic Personality in 127 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare outcomes after 6-month maintenance treatment of adults diagnosed with obsessive-compulsive disorder (OCD) based on DSM-IV criteria who responded to acute treatment with serotonin reuptake inhibitors (SRIs) augmented by exposure and response prevention (EX/RP) or risperidone." | 9.20 | Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. ( Bender, J; Cahill, SP; Campeas, R; Foa, EB; Hahn, CG; Huppert, JD; Imms, P; Liebowitz, MR; Maher, MJ; McLean, CP; Pinto, A; Powers, MB; Rodriguez, CI; Rosenfield, D; Simpson, HB; Van Meter, PE; Vermes, D; Williams, MT, 2015) |
| "To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive-compulsive disorder (OCD) patients who did not show a ≥35% decrease in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) after 12-week monotherapy with selective serotonin reuptake inhibitors (SSRIs)." | 9.15 | The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. ( Atli, A; Aydin, A; Besiroglu, L; Ozdemir, O; Ozdemir, P; Selvi, Y, 2011) |
| "To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone." | 9.13 | Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. ( de Haan, L; Linszen, D; van Beveren, NJ; van den Brink, W; van der Helm, M; van Nimwegen, LJ, 2008) |
| "This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials)." | 9.10 | Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. ( Baldini Rossi, N; Hollander, E; Pallanti, S; Sood, E, 2003) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 9.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "Risperidone, an atypical neuroleptic, has been proposed for augmentation strategies in resistant obsessive-compulsive disorder (OCD)." | 9.09 | Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. ( Cassano, GB; Dell'Osso, L; Gemignani, A; Marazziti, D; Milanfranchi, A; Pfanner, C; Presta, S, 2000) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "These results suggest that OCD patients with and without comorbid chronic tic disorders or schizotypal personality disorder may respond to the addition of low-dose risperidone to ongoing SRI therapy." | 9.09 | A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. ( Epperson, CN; McDougle, CJ; Pelton, GH; Price, LH; Wasylink, S, 2000) |
| "These results suggest that risperidone augmentation is effective and well tolerated in patients with SRI-refractory obsessive-compulsive disorder." | 9.08 | Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. ( Baxter, LR; Bystritsky, A; Saxena, S; Wang, D, 1996) |
| "Outpatients who fulfilled DSM-IV criteria for bipolar I, bipolar II, or major depressive disorder and suffered from psychosis or agitation associated with their illness (N = 20) and those who had treatment-refractory DSM-IV OCD (N = 5) were started on open trials of risperidone at daily doses of 1 to 1." | 9.08 | Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995) |
| "Quinpirole (QNP) sensitization is one of the commonly used animal models of obsessive-compulsive disorder (OCD)." | 7.85 | Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. ( Hatalova, H; Pistikova, A; Radostova, D; Stuchlik, A; Vales, K, 2017) |
| "Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD)." | 7.83 | Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. ( Arumugham, SS; Hegde, A; Kalyani, BG; Math, SB; Narayanaswamy, JC; Reddy, YC, 2016) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 7.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication." | 7.78 | Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. ( Korver, N; Machielsen, M; Scheltema Beduin, AA; Swets, M, 2012) |
| "Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents." | 7.77 | Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. ( Praharaj, SK; Pratheesh, PJ; Srivastava, A, 2011) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 7.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "The aim of this study was to investigate the efficacy and safety of fluoxetine in the treatment of obsessive-compulsive disorder (OCD) in preschool children." | 7.75 | Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. ( Coskun, M; Zoroglu, S, 2009) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 7.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "The authors report on the successful treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment." | 7.73 | Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. ( Kaneko, S; Nakamura, J; Shinkai, K; Yoshimura, R, 2006) |
| "Risperidone was generally well tolerated, except for a mild transient sedation and a mild increase in appetite." | 6.71 | Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. ( Bellodi, L; Erzegovesi, S; Guglielmo, E; Siliprandi, F, 2005) |
| "Risperidone is an atypical antipsychotic that has been investigated as a treatment for several severe psychiatric disorders in children and adults." | 5.30 | Separation anxiety in children and adolescents treated with risperidone. ( Fischer, DJ; Fluent, TE; Hanna, GL, 1999) |
| "Risperidone is a highly potent and selective serotonin2 and dopamine2 receptor antagonist with a side effect profile that appears to be much more tolerable and safer than that of typical neuroleptics." | 5.29 | Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. ( Epperson, CN; Fleischmann, RL; Leckman, JF; McDougle, CJ; Price, LH; Wasylink, S, 1995) |
| "To compare outcomes after 6-month maintenance treatment of adults diagnosed with obsessive-compulsive disorder (OCD) based on DSM-IV criteria who responded to acute treatment with serotonin reuptake inhibitors (SRIs) augmented by exposure and response prevention (EX/RP) or risperidone." | 5.20 | Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. ( Bender, J; Cahill, SP; Campeas, R; Foa, EB; Hahn, CG; Huppert, JD; Imms, P; Liebowitz, MR; Maher, MJ; McLean, CP; Pinto, A; Powers, MB; Rodriguez, CI; Rosenfield, D; Simpson, HB; Van Meter, PE; Vermes, D; Williams, MT, 2015) |
| "To investigate the comparative efficacy of aripiprazole and risperidone as augmenting agents in the treatment of obsessive-compulsive disorder (OCD) patients who did not show a ≥35% decrease in the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) after 12-week monotherapy with selective serotonin reuptake inhibitors (SSRIs)." | 5.15 | The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. ( Atli, A; Aydin, A; Besiroglu, L; Ozdemir, O; Ozdemir, P; Selvi, Y, 2011) |
| "One hundred twenty-two patients with a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder were randomized in a double-blind design to groups of 6 weeks' treatment with olanzapine (n = 59) or risperidone (n = 63), with a mean dose of 11." | 5.13 | Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. ( de Haan, L; Laan, W; Linszen, D; van Beveren, N; van den Brink, W; van Nimwegen, L, 2008) |
| "To examine whether subjective well-being and craving for cannabis were different in patients with schizophrenia or related disorders treated with either olanzapine or risperidone." | 5.13 | Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. ( de Haan, L; Linszen, D; van Beveren, NJ; van den Brink, W; van der Helm, M; van Nimwegen, LJ, 2008) |
| "We studied 15 nondepressed patients with obsessive-compulsive disorder (OCD) who were nonresponders to serotonin reuptake inhibitors with an additive trial of risperidone." | 5.12 | Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. ( Baldini Rossi, N; Bloom, R; Buchsbaum, MS; Hollander, E; Newmark, R; Pallanti, S; Platholi, J; Sood, E, 2006) |
| "Thirty patients with obsessive-compulsive disorder were treated in a single-blind design with fluvoxamine plus placebo or fluvoxamine plus risperidone according to their IGT performance." | 5.11 | The advantages of choosing antiobsessive therapy according to decision-making functioning. ( Bassi, T; Bellodi, L; Cavedini, P; Zorzi, C, 2004) |
| "4 years) with DSM-IV schizophrenia or related disorders (N = 113) who were treated with olanzapine or risperidone." | 5.10 | Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. ( Beuk, N; de Haan, L; Dingemans, P; Hoogenboom, B; Linszen, D, 2002) |
| "This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive-compulsive disorder (OCD) (failure of at least two SRI trials)." | 5.10 | Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. ( Baldini Rossi, N; Hollander, E; Pallanti, S; Sood, E, 2003) |
| "Risperidone, an atypical neuroleptic, has been proposed for augmentation strategies in resistant obsessive-compulsive disorder (OCD)." | 5.09 | Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. ( Cassano, GB; Dell'Osso, L; Gemignani, A; Marazziti, D; Milanfranchi, A; Pfanner, C; Presta, S, 2000) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "These results suggest that OCD patients with and without comorbid chronic tic disorders or schizotypal personality disorder may respond to the addition of low-dose risperidone to ongoing SRI therapy." | 5.09 | A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. ( Epperson, CN; McDougle, CJ; Pelton, GH; Price, LH; Wasylink, S, 2000) |
| "Outpatients who fulfilled DSM-IV criteria for bipolar I, bipolar II, or major depressive disorder and suffered from psychosis or agitation associated with their illness (N = 20) and those who had treatment-refractory DSM-IV OCD (N = 5) were started on open trials of risperidone at daily doses of 1 to 1." | 5.08 | Risperidone in the treatment of affective illness and obsessive-compulsive disorder. ( Jacobsen, FM, 1995) |
| "These results suggest that risperidone augmentation is effective and well tolerated in patients with SRI-refractory obsessive-compulsive disorder." | 5.08 | Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. ( Baxter, LR; Bystritsky, A; Saxena, S; Wang, D, 1996) |
| "There is a now a substantial body of evidence that suggests the new antipsychotic agent, risperidone, may be safe and effective for treating psychotic, affective or behavioural symptoms associated with various disorders other than schizophrenia, schizophreniform disorder or schizo-affective disorder." | 4.81 | Does risperidone have a place in the treatment of nonschizophrenic patients? ( Schweitzer, I, 2001) |
| "Quinpirole (QNP) sensitization is one of the commonly used animal models of obsessive-compulsive disorder (OCD)." | 3.85 | Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. ( Hatalova, H; Pistikova, A; Radostova, D; Stuchlik, A; Vales, K, 2017) |
| "Risperidone is the most widely used augmenting agent in the treatment of obsessive-compulsive disorder (OCD)." | 3.83 | Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. ( Arumugham, SS; Hegde, A; Kalyani, BG; Math, SB; Narayanaswamy, JC; Reddy, YC, 2016) |
| "The aim of the study was to investigate the prevalence rates of obsessive-compulsive disorder (OCD) and hypochondriasis in schizophrenic patients treated with atypical antipsychotics (AAPs) and to investigate the different comorbidity rates of OCD and hypochondriasis between clozapine-treated patients and patients treated with other AAPs." | 3.80 | Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. ( Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L, 2014) |
| "The aim of this study is to assess efficacy of augmentation of SSRIs with risperidone or aripiprazole in youths with tic-related Obsessive-Compulsive Disorder (OCD) non responders to an SSRI monotherapy." | 3.79 | Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. ( Brovedani, P; Masi, G; Pfanner, C, 2013) |
| "The objective of the present study was to compare brain activation in patients with obsessive-compulsive disorder (OCD) who received pharmacotherapy (selective serotonin reuptake inhibitor (SSRI) or a SSRI-risperidone combination) with that in healthy controls using (99m)Tc-hexamethyl propyleneamine oxime (HMPAO) brain single photon emission tomography (SPECT)." | 3.79 | The comparison of pre- and post-treatment (99m)Tc HMPAO brain SPECT images in patients with obsessive-compulsive disorder. ( Ateşci, F; Cura, C; Kalkan Oğuzhanoğlu, N; Karadağ, F; Kıraç, S; Ozdel, O; Yüksel, D, 2013) |
| "To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication." | 3.78 | Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. ( Korver, N; Machielsen, M; Scheltema Beduin, AA; Swets, M, 2012) |
| "Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents." | 3.77 | Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. ( Praharaj, SK; Pratheesh, PJ; Srivastava, A, 2011) |
| "To investigate the association between hyperprolactinemia and variants of the dopamine D2 receptor (DRD2) gene in children and adolescents in long-term treatment with risperidone." | 3.75 | Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Miller, DD; Moline, J; Schlechte, JA; Tansey, MJ, 2009) |
| "The aim of this study was to investigate the efficacy and safety of fluoxetine in the treatment of obsessive-compulsive disorder (OCD) in preschool children." | 3.75 | Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder. ( Coskun, M; Zoroglu, S, 2009) |
| " In the present study, we examined the effect of perospirone on marble-burying behavior, which has been considered an animal model of obsessive-compulsive disorder (OCD), compared with the effects of other antipsychotics such as haloperidol and risperidone." | 3.73 | Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder. ( Egashira, N; Fujiwara, M; Harada, S; Iwasaki, K; Matsushita, M; Mishima, K; Nishimura, R; Okuno, R, 2005) |
| "The authors report on the successful treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment." | 3.73 | Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. ( Kaneko, S; Nakamura, J; Shinkai, K; Yoshimura, R, 2006) |
| "The aim of this study was to investigate the effect of risperidone on obsessive-compulsive symptoms in the treatment of schizophrenia." | 3.72 | Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study. ( Bayraktar, E; Ercan, ES; Kayahan, B; Varan, A; Veznedaroglu, B, 2003) |
| "A 15-year-old adolescent male, with Asperger's disorder, Tourette's disorder and obsessive-compulsive disorder, on a tetracycline-risperidone-sertraline treatment regimen, had an acute exacerbation of motor and vocal tics." | 3.70 | A possible tetracycline-risperidone-sertraline interaction in an adolescent. ( Couturier, J; Steele, M, 1999) |
| " Indeed, augmentation of serotonin reuptake inhibitors with the atypical neuroleptic risperidone has been suggested to be useful in obsessive-compulsive disorder (OCD)." | 3.69 | Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. ( Bouwer, C; Emsley, RA; Hawkridge, S; Stein, DJ, 1997) |
| " Patients entered the study on a stable SRI dosage and were randomized to EX/RP (N = 40), risperidone (N = 40), or placebo (N = 20)." | 2.80 | Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement? ( Foa, EB; Rosenfield, D; Simpson, HB; Wheaton, MG, 2015) |
| "Risperidone was generally well tolerated, except for a mild transient sedation and a mild increase in appetite." | 2.71 | Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. ( Bellodi, L; Erzegovesi, S; Guglielmo, E; Siliprandi, F, 2005) |
| "Risperidone is a new efficacious antipsychotic with a low propensity for extrapyramidal side effects." | 2.70 | Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. ( Bruggeman, R; Buitelaar, JK; Gericke, GS; Hawkridge, SM; Temlett, JA; van der Linden, C, 2001) |
| "Medications used in the treatment of Tourette's syndrome are thought to modulate the functioning of these neural systems." | 2.39 | Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. ( Peterson, BS, 1996) |
| "Twenty-eight patients were consecutively recruited and treated with SRI (drug(s) and doses previously administered), SGA (risperidone median dosage 1 mg/day in 14 cases, aripiprazole median dosage 3 mg/day in 14 cases) and CBT/ERP (median hours 32." | 1.72 | Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study. ( Balestrini, V; Cieri, L; Di Spigno, D; Iommi, M; Necci, R; Orazi, F; Salvati, L; Tundo, A, 2022) |
| "Given this rare manifestation of arsenic poisoning for which there is no clearly defined treatment regimen, this case suggests that the use of a combination of an antipsychotic and an antidepressant may be considered in the rare event of psychosis with obsessive-compulsive features following arsenic poisoning." | 1.46 | An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning. ( Abdel-Gawad, NM; Gharbaoui, Y; Pigott, TA; Teixeira, AL; Wu, HE, 2017) |
| "The heavy long-term use of ecstasy may induce an alteration in the brain balance between serotonin and dopamine, which might constitute a pathophysiological mechanism underlying the onset of obsessive-compulsive, depressive and psychotic symptoms." | 1.35 | Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse. ( Maggini, C; Marchesi, C; Tonna, M, 2009) |
| "Two controlled trials deal with OCS treatment in schizophrenia: the first, with clomipramine; and the second, with fluvoxamine." | 1.33 | [Obsessive-compulsive symptoms treatment in: schizophrenia]. ( Dardennes, R; Faucher, S; Ghaëm, O; Guelfi, JD, 2005) |
| "A clear double dissociation of Wisconsin Card Sorting Test and Gambling Task performances was found, with SKZ patients performing the Wisconsin Card Sorting test significantly worse than OCD patients and control subjects and OCD patients performing the Gambling Task significantly worse than SKZ and control subjects." | 1.32 | Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study. ( Angelone, SM; Bassi, T; Bellodi, L; Cavallaro, R; Cavedini, P; Mistretta, P; Ubbiali, A, 2003) |
| ""B" was an 11-year-old girl with mild mental retardation and aggression who was treated with risperidone 1 mg per day." | 1.32 | Risperidone-induced obsessive-compulsive symptoms in two children. ( Avci, A; Diler, RS; Scahill, L; Yolga, A, 2003) |
| "Risperidone is a novel and atypical agent with a dual antagonistic effect on 5-HT and D receptors." | 1.31 | Risperidone-induced obsessive-compulsive symptoms: a series of six cases. ( Alevizos, B; Christodoulou, GN; Lykouras, L; Zervas, IM, 2002) |
| "In this open case series, the dose-response relationship of atypical antipsychotic augmentation in the treatment of obsessive compulsive disorder (OCD), and the dose-severity relationship in atypical anti psychotic-induced OC symptoms were examined." | 1.31 | Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. ( Lapierre, Y; Ramasubbu, R; Ravindran, A, 2000) |
| "Risperidone is an atypical antipsychotic that has been investigated as a treatment for several severe psychiatric disorders in children and adults." | 1.30 | Separation anxiety in children and adolescents treated with risperidone. ( Fischer, DJ; Fluent, TE; Hanna, GL, 1999) |
| "Risperidone is a highly potent and selective serotonin2 and dopamine2 receptor antagonist with a side effect profile that appears to be much more tolerable and safer than that of typical neuroleptics." | 1.29 | Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. ( Epperson, CN; Fleischmann, RL; Leckman, JF; McDougle, CJ; Price, LH; Wasylink, S, 1995) |
| "The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder." | 1.29 | Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995) |
| "When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later." | 1.29 | Differential response of psychotic and obsessive symptoms to risperidone in an adolescent. ( Dryden-Edwards, RC; Reiss, AL, 1996) |
| " Patients were treated with risperidone in two different dosage groups (3 mg and 8 mg) and haloperidol (10-20 mg) and compared with eight healthy control subjects." | 1.29 | Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. ( Asenbaum, S; Brücke, T; Gössler, R; Kasper, S; Küfferle, B; Podreka, I; Tauscher, J; Topitz-Schratzberger, A; Vesely, C, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (22.05) | 18.2507 |
| 2000's | 59 (46.46) | 29.6817 |
| 2010's | 37 (29.13) | 24.3611 |
| 2020's | 3 (2.36) | 2.80 |
| Authors | Studies |
|---|---|
| Chithra, NK | 1 |
| Suhas, S | 1 |
| Sreeraj, VS | 2 |
| Venkatasubramanian, G | 1 |
| Tundo, A | 1 |
| Salvati, L | 1 |
| Cieri, L | 1 |
| Balestrini, V | 1 |
| Di Spigno, D | 1 |
| Orazi, F | 1 |
| Iommi, M | 1 |
| Necci, R | 1 |
| de Oliveira, MVS | 1 |
| de Barros, PMF | 1 |
| de Mathis, MA | 1 |
| Boavista, R | 1 |
| Chacon, P | 1 |
| Echevarria, MAN | 1 |
| Ferrão, YA | 1 |
| Vattimo, EFQ | 1 |
| Lopes, AC | 1 |
| Torres, AR | 1 |
| Diniz, JB | 1 |
| Fontenelle, LF | 1 |
| Rosário, MCD | 1 |
| Shavitt, RG | 1 |
| Miguel, EC | 1 |
| da Silva, RMF | 1 |
| Costa, DLDC | 1 |
| Beaulieu, AM | 1 |
| Tabasky, E | 1 |
| Osser, DN | 1 |
| Uvais, NA | 1 |
| Wu, HE | 1 |
| Abdel-Gawad, NM | 1 |
| Gharbaoui, Y | 1 |
| Teixeira, AL | 1 |
| Pigott, TA | 1 |
| Dwivedi, S | 2 |
| Kar, SK | 1 |
| Baptista, T | 1 |
| de Leon, J | 1 |
| Brakoulias, V | 1 |
| Stockings, E | 1 |
| Masi, G | 1 |
| Pfanner, C | 2 |
| Brovedani, P | 1 |
| Ressler, KJ | 1 |
| Rothbaum, BO | 1 |
| Simpson, HB | 7 |
| Foa, EB | 7 |
| Liebowitz, MR | 2 |
| Huppert, JD | 2 |
| Cahill, S | 1 |
| Maher, MJ | 2 |
| McLean, CP | 4 |
| Bender, J | 2 |
| Marcus, SM | 1 |
| Williams, MT | 2 |
| Weaver, J | 1 |
| Vermes, D | 2 |
| Van Meter, PE | 3 |
| Rodriguez, CI | 2 |
| Powers, M | 1 |
| Pinto, A | 2 |
| Imms, P | 2 |
| Hahn, CG | 2 |
| Campeas, R | 2 |
| Grassi, G | 1 |
| Poli, L | 1 |
| Cantisani, A | 1 |
| Righi, L | 1 |
| Ferrari, G | 1 |
| Pallanti, S | 3 |
| O'Neill, J | 1 |
| Makkos, Z | 1 |
| Rosenfield, D | 2 |
| Cahill, SP | 1 |
| Powers, MB | 1 |
| Veale, D | 1 |
| Miles, S | 1 |
| Smallcombe, N | 1 |
| Ghezai, H | 1 |
| Goldacre, B | 1 |
| Hodsoll, J | 1 |
| Kim, SW | 2 |
| Jeong, BO | 1 |
| Kim, JM | 2 |
| Shin, IS | 2 |
| Hwang, MY | 2 |
| Paul Amminger, G | 1 |
| Nelson, B | 1 |
| Berk, M | 1 |
| McGorry, P | 1 |
| Yoon, JS | 2 |
| Bloomfield, K | 1 |
| Pulliam, E | 1 |
| Schultz, E | 1 |
| Ward, WL | 1 |
| Scahill, L | 4 |
| Sukhodolsky, DG | 1 |
| Anderberg, E | 1 |
| Dimitropoulos, A | 2 |
| Dziura, J | 1 |
| Aman, MG | 2 |
| McCracken, J | 1 |
| Tierney, E | 2 |
| Hallett, V | 1 |
| Katz, K | 1 |
| Vitiello, B | 2 |
| McDougle, C | 1 |
| Rao, SA | 1 |
| Rao, MG | 1 |
| Rao, NP | 1 |
| Varambally, S | 1 |
| Gangadhar, BN | 1 |
| Wheaton, MG | 3 |
| Zandberg, LJ | 1 |
| Carpenter, JK | 2 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Hegde, A | 1 |
| Kalyani, BG | 1 |
| Arumugham, SS | 1 |
| Narayanaswamy, JC | 1 |
| Math, SB | 1 |
| Reddy, YC | 1 |
| Galfalvy, H | 1 |
| Steinman, SA | 1 |
| Wall, MM | 1 |
| Kalanthroff, E | 1 |
| Hatalova, H | 1 |
| Radostova, D | 1 |
| Pistikova, A | 1 |
| Vales, K | 1 |
| Stuchlik, A | 1 |
| Asnaani, A | 1 |
| Kaczkurkin, AN | 1 |
| Alpert, E | 1 |
| van Nimwegen, LJ | 1 |
| de Haan, L | 3 |
| van Beveren, NJ | 1 |
| van der Helm, M | 1 |
| van den Brink, W | 2 |
| Linszen, D | 3 |
| Goldstein, RB | 1 |
| Storch, EA | 1 |
| Lehmkuhl, H | 1 |
| Geffken, GR | 1 |
| Goodman, WK | 2 |
| Murphy, TK | 1 |
| Oulis, P | 1 |
| Masdrakis, VG | 1 |
| Karapoulios, E | 1 |
| Karakatsanis, NA | 1 |
| Kouzoupis, AV | 1 |
| Konstantakopoulos, G | 1 |
| Soldatos, CR | 1 |
| Praharaj, SK | 2 |
| Goyal, N | 1 |
| Sarkar, S | 1 |
| Bagati, D | 1 |
| Sinha, P | 1 |
| Sinha, VK | 1 |
| Calarge, CA | 1 |
| Ellingrod, VL | 1 |
| Acion, L | 1 |
| Miller, DD | 1 |
| Moline, J | 1 |
| Tansey, MJ | 1 |
| Schlechte, JA | 1 |
| Matsunaga, H | 1 |
| Nagata, T | 1 |
| Hayashida, K | 1 |
| Ohya, K | 1 |
| Kiriike, N | 1 |
| Stein, DJ | 2 |
| Coskun, M | 1 |
| Zoroglu, S | 1 |
| Salomoni, G | 1 |
| Grassi, M | 1 |
| Mosini, P | 1 |
| Riva, P | 1 |
| Cavedini, P | 3 |
| Bellodi, L | 4 |
| Ohtsuchi, H | 1 |
| Matsuo, K | 1 |
| Akimoto, T | 1 |
| Watanabe, Y | 1 |
| Komossa, K | 1 |
| Depping, AM | 1 |
| Meyer, M | 1 |
| Kissling, W | 1 |
| Leucht, S | 1 |
| Selvi, Y | 1 |
| Atli, A | 1 |
| Aydin, A | 1 |
| Besiroglu, L | 1 |
| Ozdemir, P | 1 |
| Ozdemir, O | 1 |
| Marsanić, VB | 1 |
| Aukst-Margetić, B | 1 |
| Grgić, N | 1 |
| Kusmić, E | 1 |
| Rickards, H | 1 |
| Cavanna, AE | 1 |
| Worrall, R | 1 |
| Nakamae, T | 1 |
| Higuma, H | 1 |
| Kanehisa, M | 1 |
| Maruyama, Y | 1 |
| Ishitobi, Y | 1 |
| Tanaka, Y | 1 |
| Tsuru, J | 1 |
| Hanada, H | 1 |
| Kodama, K | 1 |
| Isogawa, K | 1 |
| Akiyoshi, J | 1 |
| Okada, T | 1 |
| Pratheesh, PJ | 1 |
| Srivastava, A | 1 |
| Karadağ, F | 1 |
| Kalkan Oğuzhanoğlu, N | 1 |
| Yüksel, D | 1 |
| Kıraç, S | 1 |
| Cura, C | 1 |
| Ozdel, O | 1 |
| Ateşci, F | 1 |
| Scheltema Beduin, AA | 1 |
| Swets, M | 1 |
| Machielsen, M | 1 |
| Korver, N | 1 |
| Alevizos, B | 2 |
| Lykouras, L | 2 |
| Zervas, IM | 2 |
| Christodoulou, GN | 2 |
| Morinobu, S | 1 |
| Yamashita, H | 1 |
| Yamawaki, S | 1 |
| Tanaka, K | 1 |
| Ohkawa, M | 1 |
| Crocq, MA | 1 |
| Leclercq, P | 1 |
| Guillon, MS | 1 |
| Bailey, PE | 1 |
| Listernick, R | 1 |
| Sumitani, S | 3 |
| Ohmori, T | 3 |
| Diler, RS | 1 |
| Yolga, A | 1 |
| Avci, A | 1 |
| Pathak, S | 1 |
| Cottingham, EM | 1 |
| McConville, BJ | 1 |
| Cavallaro, R | 1 |
| Mistretta, P | 1 |
| Bassi, T | 2 |
| Angelone, SM | 1 |
| Ubbiali, A | 1 |
| Hollander, E | 2 |
| Baldini Rossi, N | 2 |
| Sood, E | 2 |
| Duggal, HS | 3 |
| Gabbay, V | 1 |
| Coffey, B | 1 |
| Levy, E | 1 |
| Margolese, HC | 1 |
| Sultan, S | 1 |
| Chouinard, G | 1 |
| Veznedaroglu, B | 1 |
| Ercan, ES | 1 |
| Kayahan, B | 1 |
| Varan, A | 1 |
| Bayraktar, E | 1 |
| Ke, CL | 1 |
| Yen, CF | 1 |
| Chen, CC | 1 |
| Yang, SJ | 2 |
| Chung, W | 1 |
| Yang, MJ | 1 |
| Croarkin, P | 1 |
| Nam, T | 1 |
| Waldrep, D | 1 |
| Zorzi, C | 1 |
| Erzegovesi, S | 1 |
| Guglielmo, E | 1 |
| Siliprandi, F | 1 |
| Li, X | 1 |
| May, RS | 1 |
| Tolbert, LC | 1 |
| Jackson, WT | 1 |
| Flournoy, JM | 1 |
| Baxter, LR | 2 |
| Faucher, S | 1 |
| Dardennes, R | 1 |
| Ghaëm, O | 1 |
| Guelfi, JD | 1 |
| Machida, N | 1 |
| Shiotsuka, S | 1 |
| Semba, J | 1 |
| Matsushita, M | 1 |
| Egashira, N | 1 |
| Harada, S | 1 |
| Okuno, R | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Nishimura, R | 1 |
| Fujiwara, M | 1 |
| Bloch, MH | 1 |
| Landeros-Weisenberger, A | 1 |
| Kelmendi, B | 1 |
| Coric, V | 1 |
| Bracken, MB | 1 |
| Leckman, JF | 3 |
| Buchsbaum, MS | 1 |
| Platholi, J | 1 |
| Newmark, R | 1 |
| Bloom, R | 1 |
| Yoshimura, R | 1 |
| Kaneko, S | 1 |
| Shinkai, K | 1 |
| Nakamura, J | 1 |
| Rasmussen, K | 1 |
| Sutor, B | 1 |
| Hansen, MR | 1 |
| Black, JL | 1 |
| McDougle, CJ | 5 |
| Williams, SK | 1 |
| McCracken, JT | 1 |
| Arnold, LE | 1 |
| Cronin, P | 1 |
| Grados, M | 1 |
| Ghuman, J | 1 |
| Koenig, K | 1 |
| Lam, KS | 1 |
| McGough, J | 1 |
| Posey, DJ | 1 |
| Ritz, L | 1 |
| Swiezy, NB | 1 |
| Harada, M | 1 |
| Kubo, H | 1 |
| Ueno, S | 1 |
| Ishimoto, Y | 1 |
| Taniguchi, T | 1 |
| Tomotake, M | 1 |
| Motoki, I | 1 |
| Yamauchi, K | 1 |
| Marchesi, C | 1 |
| Tonna, M | 1 |
| Maggini, C | 1 |
| Maina, G | 2 |
| Pessina, E | 1 |
| Albert, U | 1 |
| Bogetto, F | 2 |
| Oner, O | 1 |
| Oner, P | 1 |
| van Nimwegen, L | 1 |
| van Beveren, N | 1 |
| Laan, W | 1 |
| Price, LH | 3 |
| Kopala, L | 1 |
| Honer, WG | 1 |
| Remington, G | 1 |
| Adams, M | 1 |
| Giakas, WJ | 1 |
| Jacobsen, FM | 1 |
| Lombroso, PJ | 1 |
| King, RA | 1 |
| Lynch, KA | 1 |
| Chappell, PB | 1 |
| Peterson, BS | 2 |
| Fleischmann, RL | 1 |
| Epperson, CN | 2 |
| Wasylink, S | 2 |
| Saxena, S | 1 |
| Wang, D | 1 |
| Bystritsky, A | 1 |
| Chong, SA | 1 |
| Tan, CH | 1 |
| Lee, HS | 1 |
| Iruela, LM | 1 |
| Ravizza, L | 1 |
| Barzega, G | 1 |
| Bellino, S | 1 |
| Alzaid, K | 1 |
| Jones, BD | 1 |
| Berigan, TR | 1 |
| Harazin, JS | 1 |
| Küfferle, B | 1 |
| Brücke, T | 1 |
| Topitz-Schratzberger, A | 1 |
| Tauscher, J | 1 |
| Gössler, R | 1 |
| Vesely, C | 1 |
| Asenbaum, S | 1 |
| Podreka, I | 1 |
| Kasper, S | 1 |
| Dodt, JE | 1 |
| Byerly, MJ | 1 |
| Cuadros, C | 1 |
| Christensen, RC | 1 |
| Bouwer, C | 1 |
| Hawkridge, S | 1 |
| Emsley, RA | 1 |
| Dryden-Edwards, RC | 1 |
| Reiss, AL | 1 |
| Baker, RW | 1 |
| Andrade, C | 1 |
| Agid, O | 1 |
| Lerer, B | 1 |
| Mahendran, R | 1 |
| Iyo, M | 1 |
| Sekine, Y | 1 |
| Matsunaga, T | 1 |
| Tsukamoto, T | 1 |
| Takei, N | 1 |
| Mori, N | 1 |
| Fitzgerald, KD | 1 |
| Stewart, CM | 1 |
| Tawile, V | 1 |
| Rosenberg, DR | 1 |
| Steele, M | 1 |
| Couturier, J | 1 |
| Bakaras, P | 1 |
| Georgoussi, M | 1 |
| Liakos, A | 1 |
| Panagiotis, B | 1 |
| Maria, G | 1 |
| Aris, L | 1 |
| Hanna, GL | 1 |
| Fluent, TE | 1 |
| Fischer, DJ | 1 |
| Iakovlev, VA | 1 |
| Sinha, BN | 1 |
| Nizamie, SH | 1 |
| Pelton, GH | 1 |
| Koran, LM | 1 |
| Ringold, AL | 1 |
| Elliott, MA | 1 |
| Marazziti, D | 1 |
| Dell'Osso, L | 1 |
| Presta, S | 1 |
| Gemignani, A | 1 |
| Milanfranchi, A | 1 |
| Cassano, GB | 1 |
| Kawahara, T | 1 |
| Ueda, Y | 1 |
| Mitsuyama, Y | 1 |
| Ramasubbu, R | 2 |
| Ravindran, A | 1 |
| Lapierre, Y | 1 |
| Schweitzer, I | 1 |
| Bruggeman, R | 1 |
| van der Linden, C | 1 |
| Buitelaar, JK | 1 |
| Gericke, GS | 1 |
| Hawkridge, SM | 1 |
| Temlett, JA | 1 |
| Seger, A | 1 |
| Lamberti, JS | 1 |
| Kozlova, IA | 1 |
| Burelomova, IV | 1 |
| Goriunov, AV | 1 |
| Grebchenko, IuF | 1 |
| Masikhina, SN | 1 |
| Ganesan, V | 1 |
| Kumar, TC | 1 |
| Khanna, S | 1 |
| Sun, TF | 1 |
| Lin, PY | 1 |
| Wu, CK | 1 |
| Beuk, N | 1 |
| Hoogenboom, B | 1 |
| Dingemans, P | 1 |
| Pavuluri, M | 1 |
| Heidenreich, J | 1 |
| Wright, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Maximizing Treatment Outcome in OCD[NCT00389493] | 100 participants (Actual) | Interventional | 2006-10-31 | Completed | |||
| An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder[NCT00854919] | Phase 4 | 0 participants | Interventional | 2006-01-31 | Completed | ||
| Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.[NCT00564564] | Phase 4 | 21 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)[NCT02422290] | Phase 1/Phase 2 | 5 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study[NCT04978428] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-04-14 | Recruiting | ||
| Open Label Study for the Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder[NCT04775875] | 30 participants (Anticipated) | Interventional | 2020-12-01 | Enrolling by invitation | |||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Behavioral Therapy for Children and Adolescents With Tourette Syndrome: A Randomized Controlled Trial in Taiwan[NCT03621059] | 46 participants (Actual) | Interventional | 2015-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Scale ranges from 0 to 24 where 0 is beliefs are false and 24 is convinced beliefs = reality" (NCT00389493)
Timeframe: Week 0 and Week 8
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 0 | Week 8 | |
| Treatment With Exposure/Response Prevention | 6.1 | 2.4 |
| Treatment With Pill Placebo | 5.3 | 4.3 |
| Treatment With Risperidone | 5.7 | 4.5 |
Ham-D ranges from 0=no symptoms to 52 with higher numbers indicating more severe depression (NCT00389493)
Timeframe: Week 0 and Week 8
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Ham-D at Week 0 | Ham-D at Week 8 | |
| Treatment With Exposure/Response Prevention | 7.8 | 7.8 |
| Treatment With Pill Placebo | 7.7 | 7.7 |
| Treatment With Risperidone | 9.8 | 8.0 |
QLESQ ranges from 14-70, with higher scores meaning more enjoyment and satisfaction with quality of life (NCT00389493)
Timeframe: Week 0 and Week 8
| Intervention | units on a scale (Mean) | |
|---|---|---|
| QLESQ-SF Week 0 | QLESQ-SF Week 8 | |
| Treatment With Exposure/Response Prevention | 57.8 | 70.2 |
| Treatment With Pill Placebo | 56.1 | 62.6 |
| Treatment With Risperidone | 52.3 | 55.1 |
Y-BOCS ranges from 0-40, with 0 meaning no symptoms and higher numbers meaning greater symptom severity (NCT00389493)
Timeframe: Week 0 and Week 8
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Y-BOCS score at Week 0 | Y-BOCS score at Week 8 | |
| Treatment With Exposure/Response Prevention | 27.2 | 13.0 |
| Treatment With Pill Placebo | 25.9 | 23.1 |
| Treatment With Risperidone | 26.1 | 22.6 |
SAS-SR yields a mean score between 1 and 5; the higher the score, the more severe the social adjustment problems (NCT00389493)
Timeframe: Week 0 and Week 8
| Intervention | units on a scale (Mean) | |
|---|---|---|
| SAS-SR at Week 0 | SAS-SR at Week 8 | |
| Treatment With Exposure/Response Prevention | 2.3 | 1.9 |
| Treatment With Pill Placebo | 2.2 | 2.1 |
| Treatment With Risperidone | 2.3 | 2.2 |
The CY-BOCS is a semi-structured measure of OCD severity with excellent inter-rater reliability, internal consistency, and test-retest reliability. It is validated in those starting at age 7 and used in studies up to age 20. The CYBOCS differs from the adult YBOCS only in its use of simpler language. The CY-BOCS consists of 10 items which are summed up to derive the total CY-BOCS score. The total score ranges from 0-40 with higher scores indicating greater severity of OCD symptoms. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CY-BOCS Baseline | CY-BOCS Day 14 | |
| Ketamine Treatment Group | 29.00 | 26.20 |
The CGI-S is a clinician rated 7-point rating scale for the severity of a participant's illness relative to the clinician's experience of working with this particular population. The score ranges from 1-7 with higher scores indicating greater illness severity. (NCT02422290)
Timeframe: Screening, Baseline, Day 7, Day 17, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| CGI-S Baseline | CGI-S Day 14 | |
| Ketamine Treatment Group | 5.80 | 5.00 |
"The OCD-VAS is a one-item unipolar scale to assess OCD symptoms over a rapid time frame (No obsessions to Constant obsessions). The scale ranges from 0-10 with higher scores indicating higher presence of obsessions." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| OCD-VAS Baseline | OCD-VAS Day 14 | |
| Ketamine Treatment Group | 5.00 | 5.00 |
"The Y-BOCCS is self-report scale which assesses OCD symptoms on a 5-point likert scale (None to Extreme). It consists of 10 items which are summed up to derive the total Y-BOCCS score. The total score ranges from 0-40 with higher scores indicating higher prevalence of OCD symptoms." (NCT02422290)
Timeframe: Screening, Baseline, Day 1-14, 3-Month; Baseline and Day 14 pre-specified to be reported
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Y-BOCCS Baseline | Y-BOCCS Day 14 | |
| Ketamine Treatment Group | 18.25 | 16.50 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
14 reviews available for risperidone and Anankastic Personality
| Article | Year |
|---|---|
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brazil; Clomipramine; Humans; Obsessive-Compulsive Disord | 2023 |
The psychopharmacology algorithm project at the Harvard South Shore Program: An algorithm for adults with obsessive-compulsive disorder.
Topics: Adult; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clomipramine; Humans; | 2019 |
A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Obsessive-Compulsive Disorder; Paliperido | 2019 |
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clomipramine; Dibenzothiazepines; Double | 2014 |
Second-generation antipsychotics for obsessive compulsive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Humans; Obs | 2010 |
[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
Topics: Antipsychotic Agents; Autistic Disorder; Body Dysmorphic Disorders; Clomipramine; Comorbidity; Disru | 2011 |
[The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Clomipramine; Cognitive Behavio | 2011 |
[The treatment of OCD].
Topics: Antipsychotic Agents; Behavior Therapy; Clomipramine; Drug Therapy, Combination; Fluvoxamine; Humans | 2003 |
Obsessive-compulsive symptoms associated with clozapine and risperidone treatment: three case reports and review of the literature.
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Risperidone; Sc | 2004 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Comorbidity; Depressive | 2006 |
Creating more effective antidepressants: clues from the clinic.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dep | 2006 |
Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clomipramine; Clozapine; Dopamine Antagonists | 1994 |
Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Child; Clozapine; Disease Progression; Diseas | 1996 |
Does risperidone have a place in the treatment of nonschizophrenic patients?
Topics: Bipolar Disorder; Clinical Trials as Topic; Dementia; Humans; Mental Disorders; Obsessive-Compulsive | 2001 |
29 trials available for risperidone and Anankastic Personality
| Article | Year |
|---|---|
Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Thera | 2013 |
Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Implosive The | 2015 |
Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Double-Blind Me | 2016 |
Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement?
Topics: Adult; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Humans | 2015 |
Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies.
Topics: Adult; Combined Modality Therapy; Drug Synergism; Female; Humans; Implosive Therapy; Male; Middle Ag | 2015 |
Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognitive Behavioral Therapy; Combined Modality Thera | 2016 |
Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
Topics: Cognitive Behavioral Therapy; Combined Modality Therapy; Humans; Implosive Therapy; Obsessive-Compul | 2016 |
The effect of treatment on quality of life and functioning in OCD.
Topics: Adult; Cost of Illness; Female; Humans; Implosive Therapy; Male; Obsessive-Compulsive Disorder; Qual | 2017 |
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Disruptive, Impulse Control, | 2008 |
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cognitive Behavioral | 2009 |
The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Therapy, Combination; F | 2011 |
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Drug Adm | 2002 |
Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; | 2003 |
The advantages of choosing antiobsessive therapy according to decision-making functioning.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Decision Making; Drug Therapy, Combination; Fe | 2004 |
Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Antipsychot | 2005 |
Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Topics: Adult; Antipsychotic Agents; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Drug Ther | 2005 |
Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients.
Topics: Adult; Analysis of Variance; Brain; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; | 2006 |
Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.
Topics: Antipsychotic Agents; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasi | 2006 |
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug | 2008 |
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Capsules; Dose-Response Relationship, Drug | 2008 |
Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Drug Administra | 1995 |
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
Topics: Adult; Akathisia, Drug-Induced; Comorbidity; Drug Therapy, Combination; Female; Humans; Male; Middle | 1996 |
Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD).
Topics: Adult; Clomipramine; Female; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Risperidone | 1996 |
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Dopamine Antagonists; Double-Blind Method; Drug Administra | 2000 |
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; | 2000 |
Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Drug Therapy, Combination; Female; Human | 2000 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder | 2001 |
[An experience of the application of rispolept in childhood schizophrenia].
Topics: Adolescent; Antipsychotic Agents; Child; Humans; Obsessive-Compulsive Disorder; Risperidone; Schizop | 2001 |
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Comorbidity; Female; Humans; Longitudin | 2002 |
84 other studies available for risperidone and Anankastic Personality
| Article | Year |
|---|---|
Clinical utility of trifluoperazine in the treatment of obsessive-compulsive disorder: A case report.
Topics: Humans; Obsessive-Compulsive Disorder; Risperidone; Selective Serotonin Reuptake Inhibitors; Trifluo | 2022 |
Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Drug Resistance; Drug Therapy, Combination; Huma | 2022 |
Obsessive-compulsive disorder presenting with gender incongruence obsessions.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Gender Identity; Humans; Male; Obsessive-Compulsive Disorde | 2017 |
An Unusual Case of Acute Psychosis With Obsessive-Compulsive Features Following Arsenic Poisoning.
Topics: Adult; Antipsychotic Agents; Arsenic Poisoning; Citalopram; Humans; Male; Obsessive-Compulsive Disor | 2017 |
Alcohol binge drinking in OCD: A compulsive ritualistic behaviour to counter magical thinking.
Topics: Adult; Antipsychotic Agents; Binge Drinking; Ceremonial Behavior; Clonazepam; Cognitive Behavioral T | 2017 |
Positive response to clozapine augmentation in a patient with obsessive-compulsive disorder complicated by a tardive movement disorder.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Obsessive-Compulsive Disorder; Psychiatric S | 2018 |
Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Chi-Square Distribution; Child; Drug Synergism; Fema | 2013 |
Augmenting obsessive-compulsive disorder treatment: from brain to mind.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Female; Humans; Male; Obsessive-Compulsive Disor | 2013 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Fem | 2014 |
Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Female; Humans; Male; Obsessive-Compulsive Disor | 2014 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Cor | 2014 |
Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depression; Female; Humans; Male; Middle Aged; Obsessive-C | 2015 |
Russian Adoption: A Case Study With Mixed Clinical Presentation.
Topics: Adoption; Amphetamines; Antipsychotic Agents; Asperger Syndrome; Central Nervous System Stimulants; | 2015 |
Successful treatment of tuberous sclerosis with psychosis and obsessive-compulsive disorder: A case report.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Diso | 2015 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
Topics: Adult; Aftercare; Antipsychotic Agents; Comorbidity; Drug Synergism; Female; Humans; India; Male; Me | 2016 |
Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole.
Topics: Analysis of Variance; Animals; Avoidance Learning; Clomipramine; Disease Models, Animal; Dopamine Ag | 2017 |
Successful medication withdrawal after cognitive-behavioral therapy in a treatment-resistant preadolescent male with obsessive-compulsive disorder.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Dis | 2009 |
Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder.
Topics: Adult; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluvoxamine; GABA Agoni | 2009 |
Musical obsession or pseudohallucination: electrophysiological standpoint.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Therapy, Combination; Electroen | 2009 |
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Child; Child Behavior Disorders; Female; Gene Frequency; Genetic P | 2009 |
Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
Topics: Antipsychotic Agents; Child, Preschool; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans | 2009 |
Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response.
Topics: Adult; Behavior Therapy; Combined Modality Therapy; Computer Simulation; Drug Therapy, Combination; | 2009 |
Fronto-limbic abnormalities in a patient with compulsive hoarding: a 99mTc-ECD SPECT study.
Topics: Antipsychotic Agents; Benzodiazepines; Cerebrovascular Circulation; Compulsive Behavior; Cysteine; D | 2010 |
Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with risperidone and clozapine in an adolescent girl - A case report.
Topics: Adolescent; Antipsychotic Agents; Clozapine; Diagnostic Errors; Female; Fluvoxamine; Humans; Obsessi | 2011 |
Treatment practices in Tourette syndrome: the European perspective.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Aripiprazole; Atomoxetine Hydrochloride | 2012 |
Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2012 |
Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
Topics: Drug Therapy, Combination; Fluvoxamine; Galactorrhea; Gynecomastia; Humans; Male; Obsessive-Compulsi | 2011 |
The comparison of pre- and post-treatment (99m)Tc HMPAO brain SPECT images in patients with obsessive-compulsive disorder.
Topics: Adult; Case-Control Studies; Cerebral Cortex; Cerebrovascular Circulation; Drug Therapy, Combination | 2013 |
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Causality; Clozapine; Cross-Sect | 2012 |
Risperidone-induced obsessive-compulsive symptoms: a series of six cases.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Dose-Response Relationship, Drug; Femal | 2002 |
Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
Topics: Adult; Comorbidity; Drug Therapy, Combination; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disor | 2002 |
A nine-year-old girl with new-onset tics.
Topics: Antipsychotic Agents; Child; Chorea; Clonidine; Diagnosis, Differential; Female; Humans; Obsessive-C | 2003 |
Risperidone-induced obsessive-compulsive symptoms in two children.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Female; Huma | 2003 |
The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Risperid | 2003 |
Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder: a controlled, double dissociation study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Case-Control Studies; Clozapine; Corpus Striatum; Dissoc | 2003 |
Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?
Topics: Antipsychotic Agents; Dopamine; Humans; Obsessive-Compulsive Disorder; Risperidone; Serotonin | 2003 |
Obsessive-Compulsive disorder, Tourette's disorder, or pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in an adolescent? Diagnostic and therapeutic challenges.
Topics: Adolescent; Antipsychotic Agents; Autoimmune Diseases; Citalopram; Clinical Laboratory Techniques; D | 2003 |
Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
Topics: Antipsychotic Agents; Chronic Disease; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive D | 2003 |
Reduced short-term obsessive-compulsive symptoms in schizophrenic patients treated with risperidone: a single-blind prospective study.
Topics: Adult; Antipsychotic Agents; Female; Humans; Male; Obsessive-Compulsive Disorder; Prospective Studie | 2003 |
Risperidone-induced obsessive-compulsive symptoms in two children.
Topics: Child; Humans; Obsessive-Compulsive Disorder; Risperidone | 2004 |
Reply to "Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?".
Topics: Antipsychotic Agents; Brain; Dopamine; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, | 2004 |
Comment on adult baby syndrome.
Topics: Adult; Antipsychotic Agents; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Paraphilic Dis | 2004 |
[Obsessive-compulsive symptoms treatment in: schizophrenia].
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obsessive-Compulsive Disorder; Olanzapine; | 2005 |
[Case of obsessive-compulsive disorder associated with neuroleptics-induced deficit syndrome (NIDS): successfully treated by discontinuation of neuroleptics followed by SSRI].
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Fluvoxamine; Haloperidol; Human | 2005 |
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Behavior, Animal; Disease Mod | 2005 |
Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Catecholamines; Dose-Response Relati | 2006 |
Obsessive compulsive disorder treatment in patients with Down syndrome: a case series.
Topics: Adult; Antipsychotic Agents; Down Syndrome; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle A | 2006 |
Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Basal Ganglia; Benzodiazepines; Dominance, Cerebral; Dos | 2007 |
[Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Humans; Male; Middl | 2006 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
Topics: Adolescent; Amphetamine-Related Disorders; Antidepressive Agents, Tricyclic; Antipsychotic Agents; B | 2009 |
Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports.
Topics: Antipsychotic Agents; Child, Preschool; Female; Humans; Obsessive-Compulsive Disorder; Psychiatric S | 2008 |
Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Comorbidity; Dopamine Antagonists; Dose-Resp | 2008 |
Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Fluvoxamine; Humans; Isoxazoles; Male; Obses | 1994 |
Risperidone and obsessive-compulsive symptoms.
Topics: Antipsychotic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedu | 1994 |
Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Comorbidity; Depressive Disorder; Drug Therapy, Combination; Fluoxetine | 1995 |
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise | 1995 |
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
Topics: Adult; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Male; Middle Aged; Obsessive-Compulsi | 1995 |
Hoarding and clozapine-risperidone combination.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedu | 1996 |
Risperidone and obsessive-compulsive symptoms.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Humans; Obsessive-Compulsive Disorder; Risk Factors; | 1996 |
A case report of risperidone-induced obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Clomipramine; Drug Therapy, Combination; Female; Humans; Obsessive-Comp | 1997 |
Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
Topics: Drug Therapy, Combination; Fluvoxamine; Humans; Obsessive-Compulsive Disorder; Risperidone; Treatmen | 1996 |
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzamides; Brain Mapping; Dopamin | 1996 |
Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline.
Topics: 1-Naphthylamine; Humans; Male; Middle Aged; Obsessive-Compulsive Disorder; Risperidone; Selective Se | 1997 |
Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Topics: Adult; Drug Therapy, Combination; Female; Hospital Records; Humans; Male; Middle Aged; Obsessive-Com | 1997 |
Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Topics: 1-Naphthylamine; Adolescent; Antidepressive Agents; Antipsychotic Agents; Clomipramine; Hallucinatio | 1996 |
Possible dose-response relationship for risperidone in obsessive-compulsive disorder.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; O | 1998 |
Risperidone may worsen fluoxetine-treated OCD.
Topics: Acute Disease; Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Drug Th | 1998 |
Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
Topics: Adult; Comorbidity; Dopamine Antagonists; Drug Administration Schedule; Drug Therapy, Combination; H | 1999 |
Obsessive-compulsive symptoms with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fluox | 1999 |
Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report.
Topics: Adult; Dopamine Antagonists; Humans; Male; Methamphetamine; Obsessive-Compulsive Disorder; Psychoses | 1999 |
Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
Topics: Adolescent; Child; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Obsessive-Compul | 1999 |
A possible tetracycline-risperidone-sertraline interaction in an adolescent.
Topics: Adolescent; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; D | 1999 |
Development of obsessive and depressive symptoms during risperidone treatment.
Topics: Adult; Antipsychotic Agents; Depression; Humans; Male; Obsessive-Compulsive Disorder; Risperidone | 1999 |
Separation anxiety in children and adolescents treated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Anxiety; Child; Humans; Male; Obsessive-Compulsive Disorder; Rispe | 1999 |
[The new antipsychotic preparation Rispolept (risperidone)].
Topics: Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dopamine Antagonists; Humans; Obsessive | 1999 |
Risperidone-induced obsessive-compulsive symptoms: a reappraisal.
Topics: Adult; Antipsychotic Agents; Humans; Male; Obsessive-Compulsive Disorder; Psychotic Disorders; Rispe | 2000 |
A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clomipramine; Drug Therapy, Combinati | 2000 |
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Dopamine Antagonists; Female; Humans; Ma | 2000 |
Priapism associated with polypharmacy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Fluvoxamine; Humans; Male; | 2001 |
Obsessive--compulsive disorder and psychosis.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Female; Humans; Male; Obse | 2001 |
Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Topics: Adult; Antipsychotic Agents; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; | 2001 |
Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, | 2002 |
Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Topics: Adolescent; Dopamine Antagonists; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Obsessive- | 2002 |